A key goal of cancer systems biology is to use big data to elucidate the molecular networks by which cancer develops. However, to date there has been no systematic evaluation of how far these efforts have progressed. In this Analysis, we survey six major systems biology approaches for mapping and modelling cancer pathways with attention to how well their resulting network maps cover and enhance current knowledge. Our sample of 2,070 systems biology maps captures all literature-curated cancer pathways with significant enrichment, although the strong tendency is for these maps to recover isolated mechanisms rather than entire integrated processes. Systems biology maps also identify previously underappreciated functions, such as a potential role for human papillomavirus-induced chromosomal alterations in ovarian tumorigenesis, and they add new genes to known cancer pathways, such as those related to metabolism, Hippo signalling and immunity. Notably, we find that many cancer networks have been provided only in journal figures and not for programmatic access, underscoring the need to deposit network maps in community databases to ensure they can be readily accessed. Finally, few of these findings have yet been clinically translated, leaving ample opportunity for future translational studies. Periodic surveys of cancer pathway maps, such as the one reported here, are critical to assess progress in the field and identify underserved areas of methodology and cancer biology.
Subscribe to Journal
Get full journal access for 1 year
only $22.08 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17, 333–351 (2016).
Cox, J. & Mann, M. Quantitative, high-resolution proteomics for data-driven systems biology. Annu. Rev. Biochem. 80, 273–299 (2011).
LeCun, Y., Bengio, Y. & Hinton, G. Deep learning. Nature 521, 436–444 (2015).
Wang, H. et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1459–1544 (2016).
Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304 (2018).
Zhang, J. et al. International Cancer Genome Consortium Data Portal — a one-stop shop for cancer genomics data. Database 2011, bar026 (2011).
Ashburner, M. et al. Gene Ontology: tool for the unification of biology. Nat. Genet. 25, 25–29 (2000).
Kuenzi, B. M. et al. Nature Reviews Cancer - SBmaps. NDEx.org http://www.ndexbio.org/#/networkset/7cd9b57c-8322-11e9-848d-0ac135e8bacf (2019).
Pratt, D. et al. NDEx, the Network Data Exchange. Cell Syst. 1, 302–305 (2015).
Kuenzi, B. M. et al. Nature Reviews Cancer - LCpathways. NDEx.org http://www.ndexbio.org/#/networkset/d01d40d4-fcdd-11e8-8438-0ac135e8bacf (2019).
Kandasamy, K. et al. NetPath: a public resource of curated signal transduction pathways. Genome Biol. 11, R3 (2010).
Schaefer, C. F. et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 37, D674–D679 (2009).
Perfetto, L. et al. SIGNOR: a database of causal relationships between biological entities. Nucleic Acids Res. 44, D548–D554 (2016).
Chinchor, N. MUC-4 evaluation metrics. in Proc. of the Fourth Message Understanding Conference 22–29 (Morgan Kaufmann, 1992).
Shibuya, M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis. Genes Cancer 2, 1097–1105 (2011).
Zhang, F. et al. A network medicine approach to build a comprehensive atlas for the prognosis of human cancer. Brief. Bioinform. 17, 1044–1059 (2016).
Park, S. et al. An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types. Bioinformatics 32, 1643–1651 (2016).
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
Xiong, S. et al. structural basis for auto-inhibition of the NDR1 kinase domain by an atypically long activation segment. Structure 26, 1101–1115.e6 (2018).
Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).
Sit, S.-T. & Manser, E. Rho GTPases and their role in organizing the actin cytoskeleton. J. Cell Sci. 124, 679–683 (2011).
Stoeger, T., Gerlach, M., Morimoto, R. I. & Amaral, L. A. N. Large-scale investigation of the reasons why potentially important genes are ignored. PLoS Biol. 16, e2006643 (2018).
Bai, Y. et al. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Res. 74, 7217–7228 (2014).
Seiler, M. et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 23, 282–296 (2018).
Warburg, O. & Minami, S. Versuche an Überlebendem Carcinom-gewebe. Klin. Wochenschr. 2, 776–777 (1923).
Horlbeck, M. A. et al. Mapping the genetic landscape of human cells. Cell 174, 953–967.e22 (2018).
Shen, J. P. et al. Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. Nat. Methods 14, 573–576 (2017).
Wang, T. et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell 168, 890–903 (2017).
Han, K. et al. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat. Biotechnol. 35, 463–474 (2017).
Zhao, D. et al. Combinatorial CRISPR-Cas9 metabolic screens reveal critical redox control points dependent on the KEAP1-NRF2 regulatory axis. Mol. Cell 69, 699–708 (2018).
Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A. & Higgins, G. S. Oxidative phosphorylation as an emerging target in cancer therapy. Clin. Cancer Res. 24, 2482–2490 (2018).
Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
Bordbar, A. et al. Model‐driven multi‐omic data analysis elucidates metabolic immunomodulators of macrophage activation. Mol. Syst. Biol. 8, 558 (2012).
Domblides, C., Lartigue, L. & Faustin, B. Control of the antitumor immune response by cancer metabolism. Cells 8, (2019).
Duarte, N. C. et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl Acad. Sci. USA 104, 1777–1782 (2007).
Ma, H. et al. The Edinburgh human metabolic network reconstruction and its functional analysis. Mol. Syst. Biol. 3, 135 (2007).
Thiele, I. et al. A community-driven global reconstruction of human metabolism. Nat. Biotechnol. 31, 419–425 (2013).
Mardinoglu, A. et al. Integration of clinical data with a genome-scale metabolic model of the human adipocyte. Mol. Syst. Biol. 9, 649 (2013).
Mardinoglu, A. et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 3083 (2014).
Yizhak, K., Chaneton, B., Gottlieb, E. & Ruppin, E. Modeling cancer metabolism on a genome scale. Mol. Syst. Biol. 11, 817 (2015).
Shlomi, T., Benyamini, T., Gottlieb, E., Sharan, R. & Ruppin, E. Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Comput. Biol. 7, e1002018 (2011).
Jerby, L. et al. Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res. 72, 5712–5720 (2012).
Nam, H. et al. A systems approach to predict oncometabolites via context-specific genome-scale metabolic networks. PLoS Comput. Biol. 10, e1003837 (2014).
Agren, R. et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol. 10, 721 (2014).
Resendis-Antonio, O., Checa, A. & Encarnación, S. Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect. PLoS One 5, e12383 (2010).
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Baldwin, A., Pirisi, L. & Creek, K. E. NFI-Ski interactions mediate transforming growth factor beta modulation of human papillomavirus type 16 early gene expression. J. Virol. 78, 3953–3964 (2004).
Wilting, S. M. et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med. Genomics 2, 32 (2009).
Bodelon, C. et al. Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis 37, 188–196 (2016).
Wu, Q.-J. et al. Detection of human papillomavirus-16 in ovarian malignancy. Br. J. Cancer 89, 672 (2003).
Jeannot, E., Harlé, A., Holmes, A. & Sastre-Garau, X. Nuclear factor I X is a recurrent target for HPV16 insertions in anal carcinomas. Genes Chromosomes Cancer 57, 638–644 (2018).
zur Hausen, H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl Cancer Inst. 92, 690–698 (2000).
Marullo, R. et al. HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. Carcinogenesis 36, 1397–1406 (2015).
Roos, P., Orlando, P. A., Fagerstrom, R. M. & Pepper, J. W. In North America, some ovarian cancers express the oncogenes of preventable human papillomavirus HPV-18. Sci. Rep. 5, 8645 (2015).
Ingerslev, K. et al. High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infect. Agent. Cancer 11, 39 (2016).
Rosa, M. I. et al. The prevalence of human papillomavirus in ovarian cancer: a systematic review. Int. J. Gynecol. Cancer 23, 437–441 (2013).
Meng, Z., Moroishi, T. & Guan, K.-L. Mechanisms of Hippo pathway regulation. Genes. Dev. 30, 1–17 (2016).
Shin, S.-Y. et al. Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res. 70, 6715–6724 (2010).
Aldridge, B. B., Saez-Rodriguez, J., Muhlich, J. L., Sorger, P. K. & Lauffenburger, D. A. Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. PLoS Comput. Biol. 5, e1000340 (2009).
Kolch, W., Calder, M. & Gilbert, D. When kinases meet mathematics: the systems biology of MAPK signalling. FEBS Lett. 579, 1891–1895 (2005).
Orton, R. J. et al. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem. J. 392, 249–261 (2005).
Heinrich, R., Neel, B. G. & Rapoport, T. A. Mathematical models of protein kinase signal transduction. Mol. Cell 9, 957–970 (2002).
Pan, S. Modeling the mitogen activated protein (MAP)-kinase pathway using ordinary differential equations. Comput. Biol. Bioinf. 1, 6–9 (2013).
Tran, P. T. et al. Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci. Transl Med. 3, 103ra99 (2011).
Claas, A. M., Atta, L., Gordonov, S., Meyer, A. S. & Lauffenburger, D. A. Systems modeling identifies divergent receptor tyrosine kinase reprogramming to MAPK pathway inhibition. Cell. Mol. Bioeng. 11, 451–469 (2018).
Morris, M. K., Clarke, D. C., Osimiri, L. C. & Lauffenburger, D. A. Systematic analysis of quantitative logic model ensembles predicts drug combination effects on cell signaling networks. CPT Pharmacomet. Syst. Pharmacol. 5, 544–553 (2016).
Gierut, J. J. et al. Network-level effects of kinase inhibitors modulate TNF-α–induced apoptosis in the intestinal epithelium. Sci. Signal. 8, ra129 (2015).
Lorz, A., Botesteanu, D.-A. & Levy, D. Modeling cancer cell growth dynamics in vitro in response to antimitotic drug treatment. Front. Oncol. https://doi.org/10.3389/fonc.2017.00189 (2017).
Palacios-Moreno, J. et al. Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts. PLoS Comput. Biol. 11, e1004130 (2015).
Choudhary, K. S. et al. EGFR signal-network reconstruction demonstrates metabolic crosstalk in EMT. PLoS Comput. Biol. 12, e1004924 (2016).
Gill, M. K. et al. A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. Nat. Commun. 9, 3510 (2018).
O’Connor, C. M. et al. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene 39, 703–717 (2019).
Alvarez, M. J. et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat. Genet. 48, 838–847 (2016).
Coleman, D. J. et al. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene 38, 5658–5669 (2019).
Risom, T. et al. Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat. Commun. 9, 3815 (2018).
Echeverria, G. V. et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci. Transl Med. 11, eaav0936 (2019).
Parker, L. A. et al. Diagnostic biomarkers: are we moving from discovery to clinical application? Clin. Chem. 64, 1657–1667 (2018).
Poste, G. Bring on the biomarkers. Nature 469, 156–157 (2011).
Carbone, D. P. et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J. Thorac. Oncol. 7, 1653–1660 (2012).
Amann, J. M. et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J. Thorac. Oncol. 5, 169–178 (2010).
Filho, O. M., Ignatiadis, M. & Sotiriou, C. Genomic Grade Index: an important tool for assessing breast cancer tumor grade and prognosis. Crit. Rev. Oncol. Hematol. 77, 20–29 (2011).
Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
Jerevall, P.-L. et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br. J. Cancer 104, 1762–1769 (2011).
Ma, X.-J. et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res. 14, 2601–2608 (2008).
Filipits, M. et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17, 6012–6020 (2011).
Sparano, J. A. et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373, 2005–2014 (2015).
Cronin, M. et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 53, 1084–1091 (2007).
van ’t Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
Silvestri, G. A. et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N. Eng. J. Med. 373, 243–251 (2015).
Yeoh, E.-J. et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133–143 (2002).
Stein, R. C. et al. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technol. Assess. Winch. Engl. 20, 1–201 (2016).
Michiels, S., Ternès, N. & Rotolo, F. Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. Ann. Oncol. 27, 01–09 (2016).
Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). J. Mol. Diagn. 17, 251–264 (2015).
Harris, J. FDA approves FoundationOne CDx, CMS agrees to cover. OncLive, November (2017).
Dacic, S. & Nikiforova, M. N. Present and future molecular testing of lung carcinoma. Adv. Anat. Pathol. 21, 94–99 (2014).
Rashdan, S. & Gerber, D. E. Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies. Ann. Transl Med. 4, 529 (2016).
Biankin, A. V., Piantadosi, S. & Hollingsworth, S. J. Patient-centric trials for therapeutic development in precision oncology. Nature 526, 361–370 (2015).
Senft, D., Leiserson, M. D. M., Ruppin, E. & Ronai, Z. A. Precision oncology: the road ahead. Trends Mol. Med. 23, 874–898 (2017).
Mailman, M. D. et al. The NCBI dbGaP database of genotypes and phenotypes. Nat. Genet. 39, 1181–1186 (2007).
Clough, E. & Barrett, T. The Gene Expression Omnibus database. Methods Mol. Biol. Clifton NJ 1418, 93–110 (2016).
Jones, P. et al. PRIDE: a public repository of protein and peptide identifications for the proteomics community. Nucleic Acids Res. 34, D659–D663 (2006).
Mani, R., St.Onge, R. P., Hartman, J. L., Giaever, G. & Roth, F. P. Defining genetic interaction. Proc. Natl. Acad. Sci. 105, 3461–3466 (2008).
Collins, S. R. et al. Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature 446, 806–810 (2007).
Costanzo, M. et al. A global genetic interaction network maps a wiring diagram of cellular function. Science 353, aaf1420 (2016).
Costanzo, M. et al. The genetic landscape of a cell. Science 327, 425–431 (2010).
Havugimana, P. C. et al. A census of human soluble protein complexes. Cell 150, 1068–1081 (2012).
Brückner, A., Polge, C., Lentze, N., Auerbach, D. & Schlattner, U. Yeast two-hybrid, a powerful tool for systems biology. Int. J. Mol. Sci. 10, 2763–2788 (2009).
Remy, I. & Michnick, S. W. Application of protein-fragment complementation assays in cell biology. BioTechniques 42, 137–145 (2007).
Bürckstümmer, T. et al. An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat. Methods 3, 1013–1019 (2006).
Dunham, W. H., Mullin, M. & Gingras, A.-C. Affinity-purification coupled to mass spectrometry: basic principles and strategies. Proteomics 12, 1576–1590 (2012).
Margolin, A. A. et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7, S7 (2006).
Lefebvre, C. et al. A human B‐cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol. Syst. Biol. 6, 377 (2010).
Olow, A. et al. An atlas of the human kinome reveals the mutational landscape underlying dysregulated phosphorylation cascades in cancer. Cancer Res. 76, 1733–1745 (2016).
Lachmann, A., Giorgi, F. M., Lopez, G. & Califano, A. ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information. Bioinformatics 32, 2233–2235 (2016).
Leiserson, M. D. M. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47, 106–114 (2015).
Vandin, F., Upfal, E. & Raphael, B. J. Algorithms for detecting significantly mutated pathways in cancer. J. Comput. Biol. 18, 507–522 (2011).
Jia, P. & Zhao, Z. VarWalker: personalized mutation network analysis of putative cancer genes from next-generation sequencing data. PLoS Comput. Biol. 10, e1003460 (2014).
Park, J. et al. AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget 6, 20697–20710 (2015).
Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10, 1108–1115 (2013).
Bidkhori, G. et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc. Natl Acad. Sci. 115, E11874–E11883 (2018).
Bordbar, A., Monk, J. M., King, Z. A. & Palsson, B. O. Constraint-based models predict metabolic and associated cellular functions. Nat. Rev. Genet. 15, 107–120 (2014).
Szklarczyk, D. et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447–D452 (2015).
Olcina, M. M. et al. Mutations in an innate immunity pathway are associated with poor overall survival outcomes and hypoxic signaling in cancer. Cell Rep. 25, 3721–3732.e6 (2018).
Babaei, S., Hulsman, M., Reinders, M. & de Ridder, J. Detecting recurrent gene mutation in interaction network context using multi-scale graph diffusion. BMC Bioinformatics 14, 29 (2013).
The authors gratefully acknowledge the support for this work provided by grants from the US National Institutes of Health to T.I. (CA209891, CA184427, ES014811) and B.M.K. (CA212456).
The authors declare no competing interests.
Peer review information
Nature Reviews Cancer thanks A. Mardinoglu, M. Vidal, D. Hill and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
American Association for Cancer Research project Genomics Evidence Neoplasia Information Exchange: http://www.aacr.org/Research/Research/Pages/aacr-project-genie.aspx
Cancer Systems Biology Consortium: http://csbconsortium.org/
Gene Ontology: http://geneontology.org/
Human Protein Atlas: http://proteinatlas.org/
Network Data Exchange: http://www.ndexbio.org
Oncology Research Information Exchange Network: http://oriencancer.org
Quantum Immuno-oncology Lifelong Trial programme: https://clinicaltrials.gov/ct2/results?term=QUILT
- Fuzzy logic
A predictive model that attempts to use vague or imprecise information to obtain accurate predictions and solve complex problems.
- Adjacency matrix
A square matrix used to represent the structure of a finite network in which rows and columns represent nodes in the network and the binary elements of the matrix represent the edges.
- Interaction list
A simple, tabular network representation containing two columns (source and target) detailing the edges of a network.
An open-source software platform for visualizing complex networks and integrating these with any type of attribute data for further analyses.
- Functional enrichment analysis
A method to identify collections of genes or proteins (often disease-associated pathways) that are over represented or under represented in a large set of genes or proteins.
- Hypergeometric test
A statistical test used to calculate the statistical significance of having drawn specific successes from a given population, often used to identify subpopulations that are over represented or under represented in that population.
- F score
A measure of a test’s accuracy that takes into account both the precision and the recall of the test to compute the score. Similarly to precision and recall, the F score has a highest value of 1 and a lowest value of 0.
A database of known and predicted protein–protein interactions that includes both direct (physical) and indirect (functional) interactions.
The phenomenon whereby genetic alterations at two or more genetic loci (for example, mutations or deletions in different genes) produce a phenotype that is unexpected on the basis of the phenotypes of each of the single genetic alterations.
- CRISPR interference
A genetic perturbation technique that allows sequence specific repression of gene expression in prokaryotic and eukaryotic cells.
- Network diffusion
A method to analyse how the topology of a network impacts how information spreads across a given network.
- Striatin-interacting phosphatase and kinase (STRIPAK) and integrator complex
An evolutionarily conserved supramolecular protein complex which regulates the phosphorylation status and therefore activation status of various pathways.
- k-nearest neighbours model
A non-parametric machine learning method used for classification and regression tasks that learns to classify new cases on the basis of a similarity measure (for example, distance functions).
- Basket trials
Trials designed to test the effects of a single drug, or a combination of drugs, in a variety of cancer types on the basis of the presence of a specific biomarker.
- Umbrella trials
Trials designed to test the effect of different drugs on the basis of the presence of different biomarkers within a single cancer type.
- k-fold cross validation
A resampling procedure used to evaluate machine learning models on a limited data sample by repeatedly splitting the data into training and test sets.
About this article
Cite this article
Kuenzi, B.M., Ideker, T. A census of pathway maps in cancer systems biology. Nat Rev Cancer 20, 233–246 (2020). https://doi.org/10.1038/s41568-020-0240-7